Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis

Annals of Neurology
Hillel S PanitchPsuedobulbar Affect in Multiple Sclerosis Study Group

Abstract

To evaluate the efficacy and safety of DM/Q (capsules containing dextromethorphan [DM] and quinidine [Q]) compared with placebo, taken twice daily, for the treatment of pseudobulbar affect over a 12-week period in multiple sclerosis patients. A total of 150 patients were randomized in a double-blind, placebo-controlled study to assess pseudobulbar affect with the validated Center for Neurologic Study-Lability Scale. Each patient also recorded the number of episodes experienced between visits, estimated quality of life and quality of relationships on visual analog scales, and completed a pain rating scale. Patients receiving DM/Q had greater reductions in Center for Neurologic Study-Lability Scale scores than those receiving placebo (p < 0.0001) at all clinic visits (days 15, 29, 57, and 85). All secondary end points also favored DM/Q, including the number of crying or laughing episodes (p <or= 0.0077), quality of life (p < 0.0001), quality of relationships (p = 0.0001), and pain intensity score (p = 0.0271). DM/Q was well tolerated; only dizziness occurred with greater frequency than with placebo. Results in multiple sclerosis patients were similar to those of a previous study in amyotrophic lateral sclerosis, demonstrating tha...Continue Reading

References

Oct 1, 1979·Neurology·J K WolfM Thorpy
Dec 1, 1989·Trends in Pharmacological Sciences·F C TortellaN G Bowery
Aug 1, 1986·British Journal of Clinical Pharmacology·T InabaW A Mahon
Oct 1, 1984·Archives of Neurology·F UdakaM Kameyama
Aug 1, 1996·The Australian and New Zealand Journal of Psychiatry·F L DarkM A Ron
Dec 1, 1996·Clinical Neuropharmacology·S Iannaccone, L Ferini-Strambi
Jul 1, 1997·Journal of Neurology, Neurosurgery, and Psychiatry·S R MooreR A Smith
Apr 23, 2003·Biological Psychiatry·Craig H MallinckrodtGary D Tollefson
Oct 27, 2004·Neurology·B R BrooksUNKNOWN AVP-923 ALS Study Group
Dec 9, 2004·Multiple Sclerosis : Clinical and Laboratory Research·Richard A SmithRonald A Thisted
Jan 3, 2006·The Journal of Neuropsychiatry and Clinical Neurosciences·Randolph Schiffer, Laura E Pope

❮ Previous
Next ❯

Citations

Apr 20, 2010·Der Nervenarzt·P KraftK V Toyka
May 16, 2007·Journal of Neurology·Anthony Feinstein
Apr 9, 2010·Journal of Neurology·Roy E StrowdMustafa S Siddiqui
Jul 5, 2012·Journal of Neurology·A TruiniG Cruccu
Jun 28, 2008·Current Treatment Options in Cardiovascular Medicine·Preethi Balakrishnan, Howard Rosen
Jun 11, 2011·Advances in Therapy·Susan S WorkRandall E Kaye
Sep 4, 2012·Advances in Therapy·Jennifer ColamonicoWalter Bradley
Oct 8, 2014·Acta Neuropsychiatrica·Tatjana ProkšeljAleš Kogoj
Dec 20, 2007·The Neurologist·Jeffrey A Wilken, Cynthia Sullivan
Sep 13, 2007·The Neurologist·Linda L WerlingUrsula Calef
Jun 11, 2008·Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology·Ruth Elaine Nieuwenhuis-MarkAd Vingerhoets
May 7, 2011·Current Opinion in Psychiatry·Apostolos Iacovides, Elias Andreoulakis
Jan 13, 2009·Drugs of Today·Howard Rosen
Apr 12, 2011·CNS Drugs·Karly P Garnock-Jones
Jan 1, 2012·The Primary Care Companion to CNS Disorders·Erick Messias, Betty Everett
Apr 8, 2014·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Edna Patatanian, Jessica Casselman
Jan 18, 2008·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Caren McHenry Martin
Jan 7, 2016·Issues in Mental Health Nursing·Marian W Roman
Mar 18, 2010·International Review of Psychiatry·Thomas PaparrigopoulosGeorge N Papadimitriou
Jan 31, 2016·Pharmacology & Therapeutics·Linda NguyenRae R Matsumoto
Feb 24, 2016·Journal of Pain and Symptom Management·Young D ChangTerrence Gutgsell
Jan 1, 2013·Multiple Sclerosis and Related Disorders·A FeinsteinH Lassman
Dec 26, 2015·Survey of Ophthalmology·Christopher Eckstein, M Tariq Bhatti
Nov 24, 2006·Mayo Clinic Proceedings·Josef ParviziStanley Tuhrim
Feb 3, 2009·Parkinsonism & Related Disorders·Lisa PhuongDaniel Weintraub
Sep 16, 2008·Journal of Pain and Symptom Management·Steven P CohenJianren Mao
May 28, 2008·Journal of the Neurological Sciences·Guy HaimanAriel Miller
Oct 17, 2007·The Psychiatric Clinics of North America·Lydia A Chwastiak, Dawn M Ehde
Apr 17, 2007·Journal of the Neurological Sciences·Ariel Miller, Hillel Panitch
Feb 23, 2007·Annals of Neurology·S Claiborne Johnston, Stephen L Hauser
Jan 11, 2007·Annals of Neurology·Howard J Rosen, Jeffrey Cummings
Sep 15, 2010·Annals of Neurology·Erik P PioroUNKNOWN Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators
Mar 23, 2011·The Mount Sinai Journal of Medicine, New York·Aliza Bitton Ben-Zacharia
Mar 23, 2013·Neuroscience and Biobehavioral Reviews·Edward C LauterbachPreetha Sharone Kuppuswamy
May 4, 2016·Pharmacology & Therapeutics·Charles P TaylorRae R Matsumoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.